Therefore, this proof-of-concept study not only builds upon existing data highlighting this potentially promising therapeutic approach25,26,27,28 but also paves the way for future development of a first-in-class MDM2 dimerization disruptor peptide, capable of treating a broad spectrum of MDM2/MDMX-dependent cancers, irrespective of TP53 mutational status. The gene discussed is MDM4; the disease is cancer.